Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1293 participants.

Also called NCT03794336

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,293 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03794336
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03794336. Randomized; no masking; primary purpose treatment. Start 2019-06-29 (actual); primary completion 2020-12-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
Acronym
ACADEMIC
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Alogliptin
Intervention (Drug)
Acarbose
Intervention (Drug)
Metformin
Intervention (Drug)
Aspirin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03794336
Content hash
146352b818fe03137f75ab3147f5f44b2a45201df1053814bd3b9c79f3b23c3c